Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …

Prevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new
cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced …

Objective To collect outcome data in a large cohort of patients with aggressive pituitary
tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) …

Pituitary adenomas are currently classified by histological, immunocytochemical and
numerous ultrastructural characteristics lacking unequivocal prognostic correlations. We …

Dopamine agonists are usually very effective in the treatment of prolactinomas.
Nonetheless, a subset of individuals does not respond satisfactorily to these agents, and this …

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …

Context Pituitary carcinoma is a rare and aggressive malignancy with a poor prognosis and
few effective treatment options. Case A 35-year-old woman presented with an aggressive …

Pituitary adenomas are common intracranial tumors that are mainly considered as benign.
Rarely, these tumors can exhibit an aggressive behavior, characterized by gross invasion of …

Context/Objective: Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas
respond poorly to conventional therapy and cytotoxic drugs. Temozolomide (TMZ) is an oral …

Background Dopamine agonist resistance in prolactinoma is an infrequent phenomenon.
Doses of cabergoline (CAB) of up to 2.0 mg/week are usually effective in controlling …